Avicanna recently announced the supply and licensing agreement for two products.
In a recent press release (1), Avicanna, “a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products”, recently disclosed the supply and licensing agreement for two topical products with a multinational pharmaceutical company (Pharma).
“We look forward to expanding our proprietary topical products into the European region and to be doing so through the utilization of our own international infrastructure for manufacturing,” Aras Azadian, CEO of Avicanna, said. “We are confident that through this strategic relationship and the Pharma’s established commercial infrastructure, we can facilitate the expansion of our proprietary products into several international markets.”
The multinational pharmaceutical enterprise markets and produces a variety of pharmaceutical products throughout four continents (1). Pharma has also built a commercial infrastructure in Europe where the products involved in the supply and licensing agreement will be introduced. In 2024, the company intends to market the items in six European countries, which will be expanded in the future. Licensing fees will be awarded to Avicanna and both companies have reached an agreement on minimum order quantities and Pharma’s efforts on exclusivity (1).
According to the press release, the products involved with the agreement are (1):
The Ultra-CBD cream is a 3% cannabidiol (CBD) localized cream developed to target dermatology conditions. The cream is enrolled in previously announced observational real world evidence clinical trial with the Hospital for Sick Children related to Epidermolysis Bullosa.
The Ultra-CBD cream and CBG Transdermal Gel both have completed dossiers and are planning to be commercialized and registered through cosmetics legislation applicable to the products (1). With those needs met, the product offerings are anticipated to be introduced to the marketplace sometime within the first half of 2024.
Reference
Ep 27: Tracking Strains in Diverse Landscapes
July 2nd 2025In this latest installment of Noid Knowledge, we are joined by Daniela Vergara, PhD, Hemp Specialist at the Cornell Cooperative Extension, and Anna Schwabe, PhD, Associate Lecture Professor at the University of Colorado, discussing the evolution of cannabis cultivation and the need for regional climate data. Their recent project, funded by the Agricultural Genomics Foundation, studies 10 cannabis varieties grown by farmers in different regions, specifically plant characteristics, soil type, and harvest metrics. They aim to understand how environmental factors affect cannabis yield and quality, providing actionable insights for farmers and breeders.
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.
Best of the Week: June 27 – July 03, 2025
July 4th 2025Here, we bring you our top five recent articles covering cannabis on state-tribal cannabis regulations in Montana, our podcast discussion on cannabis cultivation, our blog on compliance with federal regulations, public commentary on new standards, and hemp packaging enforcement in Florida.